Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging tool could help spot cancerous bone tumors earlier

NCT ID NCT04884048

Diagnosis Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new structured reporting system called BTI-RADS to help doctors better assess bone tumors from X-rays, CT, and MRI scans. Researchers analyzed images from 1,100 patients to see if the tool could more accurately tell which tumors are likely cancerous. The goal is to improve diagnosis and guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this tool could help doctors more accurately identify which bone tumors are likely cancerous, leading to better and faster treatment decisions.
What could go wrong
This is a validation study, not a treatment trial. The tool may not prove more accurate than current methods, and results may not apply to all hospitals or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,100 people

The number who actually took part.

Started

May 2021

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients referred for the initial imaging characterization of focal bone lesions.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient evaluated for the initial imaging characterization of a focal bone lesion. * Availability of conventional radiographs or a CT study for patients with lesions in the spine, pelvis or calvarium. * Availability of a contrast enhanced MRI study. Exclusion Criteria: * Prio surgery * History of neoadjuvant threatment * Contra-indications to contrast enhanced MRI * Diffuse bone pathology

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bone cancer bone neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone neoplasm

Contacts and locations

Locations

  • CHRU Besançon

    Besançon, 25000, France

  • CHRU Lille

    Lille, Nord, 59037, France

  • Centre Oscar Lambret

    Lille, Nord, 59000, France

  • Chu Bordeaux

    Bordeaux, 33000, France

  • Groupement des Hopitaux de l'institut catholique de Lille

    Lille, Nord, 59020, France

  • Hôpital Universitaire Paris Centre site Cochin APHP

    Paris, Ille de France, 75014, France

  • Hôpital de Purpan - CHU Toulouse

    Toulouse, 31300, France

  • University hospital of Nancy

    Nancy, Grand Est, 54000, France

  • Université Lyon 1 - Centre Hospitalier Lyon-Sud

    Lyon, 69310, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.